254 related articles for article (PubMed ID: 23255615)
1. EGFR activity is required for renal tubular cell dedifferentiation and proliferation in a murine model of folic acid-induced acute kidney injury.
He S; Liu N; Bayliss G; Zhuang S
Am J Physiol Renal Physiol; 2013 Feb; 304(4):F356-66. PubMed ID: 23255615
[TBL] [Abstract][Full Text] [Related]
2. Class I HDAC activity is required for renal protection and regeneration after acute kidney injury.
Tang J; Yan Y; Zhao TC; Gong R; Bayliss G; Yan H; Zhuang S
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F303-16. PubMed ID: 24808536
[TBL] [Abstract][Full Text] [Related]
3. EGFR drives the progression of AKI to CKD through HIPK2 overexpression.
Xu L; Li X; Zhang F; Wu L; Dong Z; Zhang D
Theranostics; 2019; 9(9):2712-2726. PubMed ID: 31131063
[TBL] [Abstract][Full Text] [Related]
4. Src family kinases regulate renal epithelial dedifferentiation through activation of EGFR/PI3K signaling.
Zhuang S; Duan M; Yan Y
J Cell Physiol; 2012 May; 227(5):2138-44. PubMed ID: 21780115
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of the mixed lineage leukemia 1-menin interaction aggravates acute kidney injury induced by folic acid and ischemia-reperfusion in mice.
Hou X; Cui B; Qiu A; Liu N; Zhuang S
Am J Physiol Renal Physiol; 2023 Nov; 325(5):F669-F680. PubMed ID: 37733875
[TBL] [Abstract][Full Text] [Related]
6. Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury.
Chen J; Chen JK; Harris RC
Kidney Int; 2012 Jul; 82(1):45-52. PubMed ID: 22418982
[TBL] [Abstract][Full Text] [Related]
7. Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury.
Tang J; Liu N; Tolbert E; Ponnusamy M; Ma L; Gong R; Bayliss G; Yan H; Zhuang S
Am J Pathol; 2013 Jul; 183(1):160-72. PubMed ID: 23684791
[TBL] [Abstract][Full Text] [Related]
8. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.
Matsuo M; Sakurai H; Ueno Y; Ohtani O; Saiki I
Cancer Sci; 2006 Feb; 97(2):155-62. PubMed ID: 16441427
[TBL] [Abstract][Full Text] [Related]
9. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
10. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
[TBL] [Abstract][Full Text] [Related]
11. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
Young NR; Liu J; Pierce C; Wei TF; Grushko T; Olopade OI; Liu W; Shen C; Seiwert TY; Cohen EE
Mol Oncol; 2013 Jun; 7(3):359-68. PubMed ID: 23200321
[TBL] [Abstract][Full Text] [Related]
12. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
[TBL] [Abstract][Full Text] [Related]
13. Exocyst Sec10 protects renal tubule cells from injury by EGFR/MAPK activation and effects on endocytosis.
Fogelgren B; Zuo X; Buonato JM; Vasilyev A; Baek JI; Choi SY; Chacon-Heszele MF; Palmyre A; Polgar N; Drummond I; Park KM; Lazzara MJ; Lipschutz JH
Am J Physiol Renal Physiol; 2014 Dec; 307(12):F1334-41. PubMed ID: 25298525
[TBL] [Abstract][Full Text] [Related]
14. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.
Sun Q; Ming L; Thomas SM; Wang Y; Chen ZG; Ferris RL; Grandis JR; Zhang L; Yu J
Oncogene; 2009 Jun; 28(24):2348-57. PubMed ID: 19421143
[TBL] [Abstract][Full Text] [Related]
15. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
[TBL] [Abstract][Full Text] [Related]
16. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.
Zhu S; Belkhiri A; El-Rifai W
Gastroenterology; 2011 Nov; 141(5):1738-48.e1-2. PubMed ID: 21741919
[TBL] [Abstract][Full Text] [Related]
17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
18. Exosome production and its regulation of EGFR during wound healing in renal tubular cells.
Zhou X; Zhang W; Yao Q; Zhang H; Dong G; Zhang M; Liu Y; Chen JK; Dong Z
Am J Physiol Renal Physiol; 2017 Jun; 312(6):F963-F970. PubMed ID: 28356285
[TBL] [Abstract][Full Text] [Related]
19. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid.
Matousovic K; Tsuboi Y; Walker H; Grande JP; Dousa TP
J Lab Clin Med; 1997 Nov; 130(5):487-95. PubMed ID: 9390636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
